RT Journal
A1 Miller A, Wang Y, Curtis J, Masoudi FA, Buxton AE, Wang TY
T1 Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: Insights from the national cardiovascular data registry
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD January 9
VO 172
IS 1
SP 64
OP 67
DO 10.1001/archinternmed.2011.466
UL http://dx.doi.org/10.1001/archinternmed.2011.466
AB 
Current guidelines predicate primary prevention cardioverter/defibrillator (ICD) implantation on patients receiving “optimal medical therapy” (OMT), defined as use of both β-blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) in the absence of contraindications.1 These recommendations promote clinical optimization of patients with low left ventricular ejection fraction (LVEF) as well as cost-effective allocation of high-cost device therapy. While prior studies hint at significant care gaps among select ICD recipients,2 the ICD Registry offered the opportunity to examine national patterns of OMT use among first-time ICD recipients in contemporary, real-world practice.